Tardive dyskinesia with low-dose, short-term neuroleptic therapy. 1976

G L Stimmel

The development, treatment, and outcome of a case of tardive dyskinesia following short-term, low-dose neuroleptic therapy is described. Thirty weeks of treatment with haloperidol, in doses never exceeding 10 mg daily, produced tardive dyskinesia symptomatology. Upon discontinuing haloperidol, the symptoms decreased significantly in severity within the first four weeks and disappeared completely within 12.5 weeks. This case is compared with the classical description of tardive dyskinesia symptomatology, etiology, response to treatment and degree of reversibility. Atypical features are explained and clinical implications of the case are offered.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010259 Paranoid Disorders Chronic mental disorders in which there has been an insidious development of a permanent and unshakeable delusional system (persecutory delusions or delusions of jealousy), accompanied by preservation of clear and orderly thinking. Emotional responses and behavior are consistent with the delusional state. Paranoia,Paranoid Psychoses,Psychoses, Paranoid,Disorder, Paranoid,Disorders, Paranoid,Paranoias,Paranoid Disorder
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G L Stimmel
January 2013, Indian journal of psychiatry,
G L Stimmel
June 1986, Archives of general psychiatry,
G L Stimmel
September 1985, Archives of general psychiatry,
G L Stimmel
August 1989, The Journal of clinical psychiatry,
G L Stimmel
May 1996, The American journal of psychiatry,
G L Stimmel
January 1987, Acta psychiatrica Belgica,
G L Stimmel
March 2010, Irish journal of psychological medicine,
G L Stimmel
January 1987, Biological psychiatry,
G L Stimmel
March 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Copied contents to your clipboard!